Suneet Agarwal, MD, PhD
Dana Farber Cancer Institute
The Agarwal lab aims to develop innovative therapies – using novel medications or a patient's own cells - for patients with genetic blood disorders.
Certain genetic disorders cause widespread disease in the body, but the principle reason for illness and death in early childhood is failure of the blood system. The Agarwal lab studies these genetic blood disorders by “turning back the clock” – using new technology in stem cell biology to take skin cells from patients with genetic blood disorders and return them to an embryonic-like state, wherein they regain the ability to form any type of cell in the body.
We believe that studying this process of going back to an embryonic-like state, and then seeing how the cells develop into different tissues (blood cells, muscle, nerves, etc.), will lead to a better understanding of what is going wrong in cells carrying these disease-causing mutations. We hope that the knowledge gained through this work will provide innovative therapies – using novel medications or perhaps even one’s own cells - for patients with genetic blood disorders, and will help develop similar strategies for patients with other rare disorders.
Suneet Agarwal is Co-Program Leader for the Stem Cell Transplant Center at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and Assistant Professor of Pediatrics at Harvard Medical School. He received his M.D. from Harvard Medical School, completed his Residency in Pediatrics at the Boston Combined Residency Program (BCRP), and was a postdoctoral fellow in pediatric hematology -oncology at the Dana Farber Cancer Institute and Children's Hospital Boston. Awarwal is certified by the American Board of Pediatrics in Pediatric Hematology and Oncology.
- Potential New Therapies for Telomere Diseases Identified: Read it on Genetic Engineering and Biotechnology News